Zacks Research Estimates Glaukos FY2028 Earnings

Why It Matters

The upgraded earnings forecast signals a potential turnaround for Glaukos, reshaping valuation expectations and attracting growth‑oriented capital. Strong analyst support and institutional ownership amplify the stock’s upside potential.

Key Takeaways

• Zacks projects FY2028 EPS $1.68, up from -$1.08
• Q1 revenue rose 35.6% YoY to $143.1M
• Consensus rating “Moderate Buy,” avg target $133.7
• Insiders sold $37M shares, now own 6.4%
• Institutional ownership exceeds 99%, showing strong backing

Pulse Analysis

Zacks Research’s FY2028 earnings projection of $1.68 per share marks a dramatic swing from the current consensus loss of $1.08, suggesting that Glaukos may be on the cusp of a profitability breakthrough. Such a forward‑looking estimate often triggers a re‑pricing of risk, especially for a medical‑device firm that has struggled with negative margins. Investors will scrutinize whether the company’s pipeline—particularly its micro‑invasive glaucoma surgery (MIGS) devices and emerging drug‑delivery platforms—can sustain the revenue momentum needed to deliver the forecasted earnings.

The latest quarterly results reinforce the revenue narrative: a 35.6% year‑over‑year increase to $143.1 million, outpacing analyst expectations. While earnings per share remained in the red at $0.28, the top‑line growth reflects expanding adoption of Glaukos’s iStent family and its broader eye‑care portfolio. Analyst houses such as UBS, Citi, and Piper Sandler have raised price targets, collectively averaging $133.69, and most maintain a "Buy" stance. This convergence of bullish price targets and a favorable earnings outlook underscores a market belief that the company’s product innovations are beginning to translate into meaningful financial performance.

Investor behavior adds another layer of context. Insider sales totaling $37 million this quarter have reduced insider holdings to 6.4%, a typical signal of liquidity needs rather than a lack of confidence, especially given the 99% institutional ownership. The stock trades at a negative PE of -31.61, reflecting past losses, but its strong balance sheet—current ratio of 4.69 and debt‑to‑equity of 0.10—provides a cushion for future growth. As analysts refine their models and institutions deepen their stakes, Glaukos appears positioned for a potential valuation uplift, contingent on delivering the earnings upside projected by Zacks.